Swiss biotech Bioversys AG shares started trading at 36.5 Swiss francs ($40.29) on the SIX Swiss Exchange on Friday, slightly up from the final price for its initial public offering (IPO) of 36 Swiss ...
The cloud weakness comes at a time when investors have grown increasingly impatient with Big Tech’s multibillion-dollar capital spending and are hungry for returns from the hefty AI investments ...